Sintilimab in Patients with Previously Treated Metastatic Neuroendocrine Neoplasms.
anti-PD-1 antibody
checkpoint blockade
immunotherapy
neuroendocrine cancers
neuroendocrine neoplasms
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
05 08 2022
05 08 2022
Historique:
received:
11
09
2021
accepted:
07
04
2022
pubmed:
2
6
2022
medline:
10
8
2022
entrez:
1
6
2022
Statut:
ppublish
Résumé
Neuroendocrine neoplasms (NENs) are a group of diseases that show high heterogeneity but have limited treatment options. This phase I study evaluated the safety and efficacy of sintilimab, anti-PD-1 monoclonal antibody, in treating advanced NENs. We prospectively enrolled patients pathologically diagnosed with NENs after standard treatment failure. Neuroendocrine neoplasms were classified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine cancers (NECs). Every patient received sintilimab, and response was assessed every 9 weeks. Twenty-four patients with a median age of 57.0 years were enrolled from November 2016 to 2017. The median Ki-67 index was 60%. Five patients had NET, 1 had NET G3, 17 had NEC, and 1 had mixed adenocarcinoma-neuroendocrine carcinoma. The most common primary tumor sites were the pancreas and gastrointestinal tract in 7 and 10 patients, respectively. In phase Ia trial, 2 patients received sintilimab 1 mg/kg every 2 weeks, one received 3 mg/kg every 2 weeks, and 21 patients enrolled in the phase Ib trial received 200 mg every 3 weeks. The objective response rate was 20.8% in all enrolled patients and 27.8% in NEC patients. The median progression-free survival was 2.2 and 2.1 months in patients with NET and NEC, respectively. The median OS was not applicable (NA) and 10.8 months (95% CI, 4.3, NA) with NET and NEC, respectively. The duration of response (DOR) was not reached, with a median follow-up time of 20.7 months. Treatment-related adverse events (TRAE) occurred in 17 (70.8%) patients. The most frequent TRAE was thyroid dysfunction (41.7%), and a grade 3 pulmonary infection occurred in 1 patient. The programmed cell death 1-ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) rate was 18.8% (3 out of 16) and the expression of PD-L1 did not correlate with response. Sintilimab was well-tolerated and showed encouraging response in NECs. NCT02937116.
Sections du résumé
BACKGROUND
Neuroendocrine neoplasms (NENs) are a group of diseases that show high heterogeneity but have limited treatment options. This phase I study evaluated the safety and efficacy of sintilimab, anti-PD-1 monoclonal antibody, in treating advanced NENs.
METHODS
We prospectively enrolled patients pathologically diagnosed with NENs after standard treatment failure. Neuroendocrine neoplasms were classified into well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine cancers (NECs). Every patient received sintilimab, and response was assessed every 9 weeks.
RESULTS
Twenty-four patients with a median age of 57.0 years were enrolled from November 2016 to 2017. The median Ki-67 index was 60%. Five patients had NET, 1 had NET G3, 17 had NEC, and 1 had mixed adenocarcinoma-neuroendocrine carcinoma. The most common primary tumor sites were the pancreas and gastrointestinal tract in 7 and 10 patients, respectively. In phase Ia trial, 2 patients received sintilimab 1 mg/kg every 2 weeks, one received 3 mg/kg every 2 weeks, and 21 patients enrolled in the phase Ib trial received 200 mg every 3 weeks. The objective response rate was 20.8% in all enrolled patients and 27.8% in NEC patients. The median progression-free survival was 2.2 and 2.1 months in patients with NET and NEC, respectively. The median OS was not applicable (NA) and 10.8 months (95% CI, 4.3, NA) with NET and NEC, respectively. The duration of response (DOR) was not reached, with a median follow-up time of 20.7 months. Treatment-related adverse events (TRAE) occurred in 17 (70.8%) patients. The most frequent TRAE was thyroid dysfunction (41.7%), and a grade 3 pulmonary infection occurred in 1 patient. The programmed cell death 1-ligand 1 (PD-L1)-positive (tumor proportion score ≥1%) rate was 18.8% (3 out of 16) and the expression of PD-L1 did not correlate with response.
CONCLUSION
Sintilimab was well-tolerated and showed encouraging response in NECs.
CLINICALTRIALS.GOV IDENTIFIER
NCT02937116.
Identifiants
pubmed: 35647908
pii: 6596625
doi: 10.1093/oncolo/oyac097
pmc: PMC9355821
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
B7-H1 Antigen
0
sintilimab
8FU7FQ8UPK
Banques de données
ClinicalTrials.gov
['NCT02937116']
Types de publication
Clinical Trial, Phase I
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e625-e632Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
J Thorac Oncol. 2018 May;13(5):636-648
pubmed: 29378266
J Clin Oncol. 2020 Dec 10;38(35):4138-4148
pubmed: 33026938
Clin Cancer Res. 2020 May 15;26(10):2337-2345
pubmed: 32086343
Cell Death Dis. 2017 Aug 24;8(8):e3004
pubmed: 28837143
Br J Cancer. 2020 Apr;122(9):1309-1314
pubmed: 32152503
Lancet Oncol. 2017 Mar;18(3):e143-e152
pubmed: 28271869
Cancer. 2020 Jul 1;126(13):3021-3030
pubmed: 32320048
Endocr Relat Cancer. 2012 Nov 06;19(6):751-7
pubmed: 22940375
J Clin Oncol. 2017 Dec 1;35(34):3823-3829
pubmed: 28813164
J Cancer. 2016 Feb 05;7(5):484-9
pubmed: 26958083
Clin Cancer Res. 2020 May 1;26(9):2124-2130
pubmed: 31980466
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Front Oncol. 2019 May 07;9:343
pubmed: 31134150
Endocr Relat Cancer. 2015 Jun;22(3):289-98
pubmed: 25770151
Cancer. 2011 Oct 15;117(20):4617-22
pubmed: 21456005